<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059341</url>
  </required_header>
  <id_info>
    <org_study_id>ELIESWTEDRP</org_study_id>
    <nct_id>NCT04059341</nct_id>
  </id_info>
  <brief_title>Early Extracorporeal Shockwave Therapy for Erectile Dysfunction in Radically Prostatectomised Men.</brief_title>
  <official_title>Early Extracorporeal Shockwave Therapy for Erectile Dysfunction in Radically Prostatectomised Men.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to assess the relationship between low intensity shock wave
      treatment (LI-SWT) and erectile function (ED) in patients who have undergone radical
      prostatectomy (RP).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, single-blinded, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Sham LI-ESWT treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>IIEF-5 Score 1</measure>
    <time_frame>One month after final treatment session</time_frame>
    <description>Change in International Index of Erectile Function (IIEF-5) score compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IIEF-5 Score 3</measure>
    <time_frame>Three months after final treatment session</time_frame>
    <description>Change in International Index of Erectile Function (IIEF-5) score compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IIEF-5 Score 6</measure>
    <time_frame>Six months after final treatment session</time_frame>
    <description>Change in International Index of Erectile Function (IIEF-5) score compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EDITS</measure>
    <time_frame>One month after final treatment session</time_frame>
    <description>Erectile Dysfunction Inventory of Treatment Satisfaction score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RigiScan</measure>
    <time_frame>One month after final treatment session</time_frame>
    <description>Change in nocturnal erections compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EHS 1</measure>
    <time_frame>One month after final treatment session</time_frame>
    <description>Change in Erection Hardness Score compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EHS 3</measure>
    <time_frame>Three months after final treatment session</time_frame>
    <description>Change in Erection Hardness Score compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EHS 6</measure>
    <time_frame>Six months after final treatment session</time_frame>
    <description>Change in Erection Hardness Score compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Erectile Dysfunction</condition>
  <condition>Extracorporeal Shockwave Therapy</condition>
  <condition>Radical Prostatectomy</condition>
  <arm_group>
    <arm_group_label>Active LI-ESWT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active group receives five sessions of low intensity extracorporeal shockwave treatment, once per week for five consecutive weeks. Treatment is initiated three weeks after radical prostatectomy and is given using DUOLITH® SD1 manufactured by STORZ MEDICAL AG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham group receives five sessions of sham low intensity extracorporeal shockwave treatment, once per week for five consecutive weeks. Treatment is initiated three weeks after radical prostatectomy and is given using DUOLITH® SD1 manufactured by STORZ MEDICAL AG with a shockwave absorbing adapter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT)</intervention_name>
    <description>Five sessions of penile Low Intensity Extracorporeal Shockwave Therapy initiated three weeks after radical prostatectomy.</description>
    <arm_group_label>Active LI-ESWT</arm_group_label>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Radically prostatectomised men

          -  Non nerve-sparing or nerve-sparing RP.

          -  Age 20-80 years

          -  Have been in a relationship for more than 3 months.

          -  Sexually active

          -  Patient can give informed consent.

        Exclusion Criteria:

          -  Men with ED of neuropathological or psychogenic origin

          -  Rectal extirpation, radiation therapy to the pelvic area and recovery from any other
             cancer within the past 5 years are excluded.

          -  Patients with heart disease prohibiting sexual activity or taking medication with
             antiandrogens, anticoagulant (apart from aspirin) or systemic use of glucocorticoids
             within 5 weeks.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ali Moumneh, BSC.med</last_name>
    <phone>+45234826423</phone>
    <email>almou15@student.sdu.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Lund, Professor</last_name>
    <email>lars.lund@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Ali Moumneh, BSc.med</last_name>
      <email>almou15@student.sdu.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Lund,MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Radical Prostatectomy</keyword>
  <keyword>Prostatectomy</keyword>
  <keyword>Nerve-sparing</keyword>
  <keyword>Non nerve-sparing</keyword>
  <keyword>Erectile dysfunction</keyword>
  <keyword>Erectile function</keyword>
  <keyword>Shockwave</keyword>
  <keyword>LI-ESWT</keyword>
  <keyword>ESWT</keyword>
  <keyword>Low intensity extracorporeal shockwave therapy</keyword>
  <keyword>extracorporeal shockwave therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

